Modulation of BACE1 Activity by Chemically Modified Aptamers - CEA - Commissariat à l’énergie atomique et aux énergies alternatives Access content directly
Journal Articles ChemBioChem Year : 2018

Modulation of BACE1 Activity by Chemically Modified Aptamers

Abstract

A modified DNA aptamer that binds BACE1, a therapeutic target involved in Alzheimer's disease has been developed. This ssXNA not only tightly binds to BACE1 but also inhibits its protease activity in vitro in the same range as a previously described unmodified aptamer. We report the in vitro selection of functional oligonucleotides incorporating two nucleobase modifications 5-chlorouracil and 7-deazaadenine. The nucleoside analogue 5-chloro-2-deoxyuridine has already been explored as a replacement for thymidine in a chemically modified genome of a bacterium. Thus, 5-chlorouracil modification is a good candidate to support genetic transfer in vivo as well as functional activity.

Dates and versions

cea-02291360 , version 1 (18-09-2019)

Identifiers

Cite

Cecile Gasse, Marwa Zaarour, Sam Noppen, Mikhail Abramov, Philippe Marliere, et al.. Modulation of BACE1 Activity by Chemically Modified Aptamers. ChemBioChem, 2018, 19 (7), pp.754-763. ⟨10.1002/cbic.201700461⟩. ⟨cea-02291360⟩
89 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More